Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Summary

Primary Objective: * To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin (IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3 courses of docetaxel/cisplatin. Secondary Objectives : * To compare the time to progression after chemotherapy treatment between the IC and DC arms of treatment. * To compare the toxicity profile of the IC and DC arms of treatment.

Timeline

Start

2005-05

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Slow recruitment”

Drugs

Indications